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Abstract: The fact that some viruses act as carcinogens has long since been known. Amongst these viruses
are some genotypes of the Human Papillomaviruses (HPVs). HPV is most frequently associated with cervical
cancer, that is, cancer of the cervix or neck of the uterus. In fact, 95-100% of all cervical cancers are caused by
infection with HPV. HPV also causes a high proportion of other anogenital cancers. In 1995, the International
Agency for Research on Cancer (IARC) concluded that HPV types 16 and 18 are carcinogenic to humans; HPV
types 31 and 33 are probably carcinogenic to humans whilst some HPV types other than 16, 18, 31 and 33 are
possibly carcinogenic to humans. This review focuses first on the structure, classification and genome of these
particular viruses. Particular attention is given to those features that play a role in the carcinogenicity of
particular HPV genotypes. Given the close association between HPV and cervical cancer, detecting the presence
of HPV in a particular patient and more specifically, the presence of particular genotypes of HPV, may give an
indication of the likelihood of progression to precancerous and cancerous changes in the cervix. In fact, there
is much evidence that screening of women with both cytology and HPV DNA tests increases sensitivity for
detection of Cervical Intraepithelial Neoplasia (CIN) 3 or cancer sufficiently to permit longer screening intervals
than with cytology alone. However, it is important to realize that the presence of HPV does not mean that a
woman has or will develop cervical disease. Thus, there is still a dilemma as regards the real utility of HPV DNA
testing. Screening and diagnostic procedures for cervical cancer will be discussed in the second part of this
review, with special emphasis on HPV DNA testing. The benefits of HPV DNA testing in specific situations will
be highlighted, particularly in the case of a diagnosis of Atypical Squamous Cell of Undetermined Significance
(ASCUS).
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INTRODUCTION
Structure: Human Papillomaviruses (HPVs) form
icosahedral, non-enveloped particles with a diameter of
approximately 55 nm. They contain a double-stranded,
supercoiled and circular DNA genome of 7500-8000 base
pairs (IARC, 1995), which weighs about 5×10 Da. Only6 
one strand of their DNA is coding (Cubie, 2007).
Papillomaviruses are resistant to organic solvents and to
heating at 56°C. HPV particles have a buoyant density of
1.34 g mLG  in caesium chloride and a sedimentation1
coefficient of 300. 
The viral capsid is composed of 72 capsomeres,
which are arranged on an icosahedral surface lattice. Sixty
of  the  capsomeres arte 6-coordinated and the remaining
12 are 5-coordinated. Capsomeres consist of a trunk with Fig. 1: Three-dimensional picture of HPV showing the
proximal and distal thickening. They associate at their capsomeres. Each capsomere is composed of 5
base and project radially. Each capsomere is made up of subunits  and  therefore  exhibits a 5-fold
5 identical subunits and therefore exhibits a 5-fold symmetry. Source: http://www.med-ars.it/virus/
symmetry (Fig. 1) (IARC, 1995). hpv1. jpg
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Table 1: Classification of HPV according to their oncogenic risk. Adapted from: Palefsky (2002)
Risk category HPV type Oncogenic risk
Low 6, 11 Rarely found in cervical cancer-mostly cause genital warts.
Intermediate 33, 35, 39, 52, 52, 56, 58, 59, 68 Found in about 25% of cervical cancers. Rarer than the high-risk types.
High 16, 18, 31, 45 Found in about 75% of cervical cancers. Types 16 and 18 are the most common
Table 2: Classification of human papillomavirus by genus, according to the international council on taxonomy of viruses
Genus Type Associated lesions
" HPV -2, -27, -57 Common skin warts, also frequently in genital warts in children 
HPV -18, -39, -45, -59 Mucosal lesions, high risk, more frequent in adenocarcinomas
HPV -16, -31, -33, -35, -52, -58, -67 Mucosal lesions, high risk, more frequent in squamous carcinomas
HPV-6, -11, -13, -44, 74 Benign mucosal lesions-genital warts, laryngeal papillomas
$ HPV-5, -8 Cutaneous benign and malignant lesions in immunosuppressed patients
( HPV-4, -65 Cutaneous benign lesions
µ HPV-1, -63 Cutaneous benign lesions, frequently on feet 
Source: Cubie (2007)
Classification: The papillomaviruses are the viruses HPV-GENOMIC ORGANIZATION
belonging to the Papillomaviridae family. Previously, they
were classified as a subfamily together with the
polyomaviruses and the vacuolating virus of rhesus
monkeys as belonging to the Papovaviridae family. These
3 groups of viruses used to be classified together because
of the similar morphology of their capsids and also
because they all contain a double-stranded and circular
deoxyribonucleic acid (DNA). However, the biology,
mode of action, genomic size and organization and
nucleotide and amino acid sequence of papillomaviruses
are different from that of the other 2 species. This
knowledge has resulted in papillomaviruses being
classified as a separate family. 
Papillomaviruses are found in birds, reptiles and in
many mammalian species (including humans), but
different types are specific to each species. They infect
squamous epithelium and mucous membranes, causing
benign warts and sometimes tumours. Different HPVs
have evolved to fill different biological niches, with the
particular tissues infected and the appearance of the
lesions produced being associated with specific virus
types (Cubie, 2007). These types are defined by genomic
analysis  and  therefore  represent  genotypes.  In  fact,
an  HPV  type  is  defined  as a complete genome where
the  sequence  of  the  L1  gene  is  at  least  10%
dissimilar that of any other type. Subtypes vary by 2-10%
in the L1 sequence, whereas variants have >2% variation
in L1. 
HPV genotypes can also be classified as low,
intermediate or high risk according to the extent of their
oncogenic potential (Table 1). More than 200 HPV types
exist and the genome of approximately 100 types has been
fully sequenced. Table 2 shows the HPV classification
according to the genus. Eight genera have been agreed
and  the  majority of HPVs fall into the alpha genus
(Cubie, 2007). 
AND ROLES OF GENE PRODUCTS
 The circular DNA genome of all papillomaviruses can
be divided  into  3  segments  of  unequal   size-the 
upstream regulatory region (URR), the early (E) region and
the late (L) region. The URR, also called the long control
region (LCC) or the non-coding region (NCR), represents
about 10% of the genome (IARC, 1995). It is involved in
the initiation of viral replication and is important for the
regulation of gene function (Cubie, 2007). The early
region, which makes up about 50% of the viral genome
(IARC, 1995), is composed of 2 large (E1 and E2) and
several smaller (E4-E7) reading frames (Cubie, 2007). The
E genes encode proteins with various regulatory
functions. The late region, on the other hand, makes up
40%  of  the  genome  and  is  made  up of 2 large genes
(L1 and L2) that code for the capsid proteins (IARC, 1995)
(Fig. 2).
The coding sequences are distributed in all open
reading frames. Genes E4, E5 and E7 encode single
polypeptide chains and each L gene encodes a single
protein. Splicing events lead to the production of different
proteins with different functions (Cubie, 2007). In fact, E1/,
E2 and E6, give rise to >1 protein through differential
splicing (IARC, 1995). 
E1 and E2 genes and proteins: The E1 gene is important
for episomal maintenance and is often disrupted by
integration (Cubie, 2007). It is the largest open reading
frame of papillomaviruses, being transcribed into
polycistronic RNAs that start at the E6/E7 promoter. It
encodes 2 known polypeptide products, the largest of
which is needed for replication. 
E2 genes of papillomaviruses encode proteins that
differ in size and which have highly conserved N-terminal
transcription activation domains of about 200 amino acids
and  highly  conserved   carboxyl-terminal  DNA  binding
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Fig. 2: The genome of HPV-16. Source: http://www.
answers.com/topic/hpv-16-genome-organi-zation-
png
domains of about 85 amino acids. These 2 domains are
linked by sequence diverse hinge regions. E2 proteins
form dimers, which function as DNA binding factors, their
carboxyl terminal domains having high specificity for the
sequence 5’-ACCGNNNNCGGT-3’. Bound to DNA
(IARC, 1995) and together with E1 E2 proteins can
function as transcription activators and repressors or as
modulators of replication (Cubie, 2007).
E4 gene and proteins: E4 proteins are involved in
maturation of virions and in their release from
differentiated keratinocytes (Cubie, 2007). In fact, E4
proteins form structured filamentous cytoplasmic
networks that co-localise with cytokeratin filaments. E4
proteins of different HPV’s have little nucleotide
sequence similarity yet they share a high proline content
(IARC, 1995). 
E5 gene and proteins: The E5 gene is not found in all
papillomaviruses and is frequently lost or remains
unexpressed after viral integration (Cubie, 2007). It is
located at the 3’ end of the early region, downstream from
the E2 gene. It is likely expressed through a polycistronic
mRNA that also encodes E2.
E5 proteins, being small and hydrophobic, interact
with transmembrane domains of  receptor  kinases,
thereby altering  their  half-life  and  responses  to  ligands
(IARC, 1995). In fact, the E5 protein has a transforming
function because it alters signaling from growth factor
receptors (Cubie, 2007). E5 proteins bind exclusively to a
16 kDa cellular protein, a component of protein ATPases
(IARC, 1995).
E6 and E7 genes and proteins: E6 and E7 genes are
located at the 5’ of the early region and are expressed in
the  form  of  a  poylcistronic mRNA transcribed from the
E6/E7 promoter. The 2 reading frames are separated by a
short variable distance. E6 genes of HPV types involved
in  malignancy  are  able  to  be spliced differentially to
shorter proteins (IARC, 1995). The E6 gene co-operates
with the E7 gene to stimulate cells into the S (Synthesis)
phase of the cell cycle. Together with E7, it also slows
down cell differentiation and increases the efficiency of
transformation (Cubie, 2007). 
E6 proteins of genital HPV’s associate with and lead
to the elimination of the tumour suppressor protein p53.
E6 proteins can also repress and activate transcription of
promoters through interactions with p53 or with the basic
transcription initiation complex (IARC, 1995). 
The E7 gene is the major transforming gene. It is
capable  of  transforming  cells independently of E6
(Cubie, 2007). The E7 gene of HPV-16 inhibits the binding
of the retinoblastoma tumour suppressor protein (pRB) to
E2 F transcription factors. It does this by forming a
complex with pRB itself (IARC, 1995). 
L1 and L2 genes and proteins: L1 and L2 proteins are part
of papillomaviruses capsids. The later genes L1 and L2 are
transcribed in BPV-1 and HPV-8 from a promoter in the
LCR and, during the generation of mRNA’s, sequences
corresponding to the early genes have to be spliced out
from the primary transcript. An equivalent promoter has
not yet been reported for genital HPV’s. Nuclear
localization signals direct the transport of the capsid
proteins into the nucleus where the viral particles are
assembled (IARC, 1995). 
Regulation of gene expression: This complex regulation
is controlled by different cellular and viral transcription
factors, different promoter usage, different splicing and
different transcriptional termination and mRNA stability.
The mechanisms have to achieve the following
phenomena, many of which are deregulated during
malignant progression of papillomaviruses lesions:
C Epithelial-specific transcription.
C Differential expression of papillomavirus genes
during the differentiation of squamous epithelia, in
particular the switch from early to late genes.
C Feedback control by papillomaviruses gene
products, which may play an important role in the
persistence of papillomaviruses infection.
C Response to physiological factors of the infected
host on papillomavirus gene expression (IARC,
1995).
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SCREENING AND DIAGNOSTIC cervical stenosis-a complication in women following
TECHNIQUES FOR CERVICAL CANCER treatment  for Cervical Intraepithelial Neoplasia (CIN).
Cervical cancer has been the first malignancy (Manivasagram et al., 2004). 
worldwide for which an effective method of screening has
been introduced. A screening  program  is needed to make Method: The ideal time for a cervical cytology examination
the public and the profession more aware of cervical is  2  weeks  after the first day of the last menstrual period.
cancer as the  potential  cause  of  even  negligible Patients should avoid sexual intercourse and douching for
gynaecologic symptoms (DiSaia and Creasman, 2002). A 24-48 h before the examination. Also, women should not
50% of cases with  invasive  cervical  cancer arise in use any intravaginal products or medicine for several
women who are not effectively screened. Early diagnosis days  before  the  smear  is  taken.  Circumstances  that
is also required because definite cure is readily attained may interfere  with  the  interpretation  of  a  cervical
when cervical cancer is minimal but almost impossible if cytology test are active menstruation, significant cervical
the tumour has been  given  enough  time  to  grow  and or  vulvovaginal  infections  and  a   timing  >8  weeks
metastasise (DiSaia and Creasman, 2002). post-partum. 
Cervical cytology visible masses or ulcerations that may indicate an
Overview: Cervical cytology (the Papanicolaou smear) invasive cervical cancer. An adequate cervical cell
involves collection of exfoliated cells from the cervix and specimen is then collected with the women in the
microscopic examination of these cells after staining. This dorsolithotomy position. A sterilized or single-use bivalve
can be used not only to identify women with invasive speculum  of  appropriate size is inserted into the vagina
cervical cancer but more importantly to identify in such a way as to allow complete visualization of the
precancerous lesions of the cervix. For this reason, cervical os and as much of the transformation zone as
cytology-based screening programs are the mainstay for possible. The cervix should not be contaminated with
cervical cancer prevention. In fact, cervical cytology is lubricant  of  water-soluble  gel  that  may obscure the
considered  as  a  screening rather than a diagnostic test smear. Therefore, the smear must be obtained before any
(IARC, 2005). A Pap smear has been shown to appreciably bimanual examination. 
increase levels of inflammatory cytokines interleukin-12 If a spatula and a conical cervical brush are used, the
(IL-12), interleukin-10 (IL-10) and tumour necrosis factor-" spatula is first placed firmly against the ectocervix with
(TNF-") in the cervix. It is still unknown, however, the long projection extending into the endocervical canal.
whether these local Pap smear-associated inflammatory The spatula is then rotated several times 360° around the
responses are one of the factors commencing long-term portio and removed. The entire transformation zone must
protection from HPV infection (Passmore et al., 2007). be sampled. Transfer is best performed by using the
There remains a question as regards the frequency at spatula to thinly spread the cells from both sides of the
which a Pap smear must be performed. While, Pap smear spatula onto the glass slide. The endocervical canal is
screening in the United States (U.S.) was initially then sampled using the conical cervical brush, which is
implemented as an annual test, analysis of data from large inserted into the canal and rotated 90-180° once. Material
screening programs suggests that annual screening from both sides of the spatula should be spread onto the
confers at best a minimal advantage over triennial slide. Cell fixation must be performed within a few seconds
screening. In light of this evidence, most U.S. professional of specimen collection to prevent air-drying. It is done by
medical societies have long since accepted that average immersing the slide in alcohol or spraying it with a
women need not undergo Pap smear screening annually. specially formulated spray fixative (IARC, 2005). 
At present, almost all industrialized nations have
screening programs in which women are screened every Liquid-based cervical cytology: Liquid-Based Cytology
2-5 years. The majority of American women report being (LBC) is a way if improving the classical cervical cytology
screened for cervical cancer more frequently than test. The cells scraped from the cervix are not spread onto
recommended (Sirovich and Welch, 2004). Yet, in general, a glass slide but are transferred to a liquid preservative
women are not open to the idea of reducing the frequency solution that is transported to the laboratory, where the
of Papanicolaou (Pap) smears, however, because of their slide is prepared. A number of different LBC techniques
perception that annual screening is successful in reducing are in use worldwide but the ThinPrep® and SurePath™
cervical cancer mortality (Smith et al., 2003). are the most widely used.
Unsatisfactory, smears may be due to the inability to As an example, the ThinPrep method will be
visualize the squamo-columnar junction as a result of considered.  Here,  clumps  of  cells  and mucus are broken
This requires increased referral to colposcopy
The cervix is first carefully inspected for grossly
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up by mechanical agitation and then, the liquid application of 5% acetic acid, using a camera and internal
preservative solution is filtered through a membrane filter light  source. The images are projected onto a screen at a
with a pore size specifically designed to trap epithelial fixed distance to simulate magnification and are
cells whilst allowing red blood cells and inflammatory cells interpreted by a trained evaluator. 
to pass through. The epithelial cells collected on the Dilute acetic acid causes a reversible coagulation of
membrane filter are then transferred onto a glass slide and intracellular proteins, resulting in noticeable opacity and
stained. This produces a thin, monolayer type preparation a decrease in the usual reddish hue imparted by the
(IARC, 2005). subepithelial vasculature. This effect, called
This method has several advantages over acetowhiteninning, is not specific to cervical neoplasia
conventional cytology. Not only is there a more and may also occur in immature squamous metaplasia and
representative transfer of cells from the collection device in inflamed, regenerating cervical epithelium. The degree
to the glass slide (Watts, 2007), but there is also a of opacity produced varies according to the thickness of
decrease in the number of unsatisfactory cytology the neoplastic change in the epithelium and thus,
specimens. Moreover, residual cellular material can be according to the grade of intraepithelial neoplasia. 
used for the preparation of other glass slides or for More recently, the application of Lugol’s solution
molecular testing (IARC, 2005). In fact, liquid-based has been used and this technique is known as Visual
cytology specimens can be used for the Inspection with Lugol’s Iodine (VILI). Lugol’s iodine
immunohistochemical staining of p16, a biomarker for the stains glycogen stored in cervical epithelial cells. Mature
primary screening of cervical cytology (Yoshida et al., squamous epithelium stores more glycogen than either
2004). columnar epithelium or immature squamous columnar
However, liquid-based cervical cytology is neither epithelium. The application of iodine to the cervix thus,
more sensitive nor more specific for detection of high- results in black or dark brown staining or immature
grade Cervical Intraepithelial Neoplasia (CIN 2 or 3) squamous epithelium. Columnar epithelium does not stain
compared with the conventional Pap test (Arbyn et al., and retains its reddish hue. Areas of immature metaplasia
2008). Suitable training for the collection of samples in a stain a very light brownish hue, if at all. Neoplastic
liquid solution could improve the adequacy of the sample squamous epithelium contains little or no glycogen and
and thus, the precision of the cytological diagnosis does not stain with Lugol’s iodine, taking a brown
(Liverani et al., 2006). mustard or saffron yellow colour. Atrophic epithelium
Visual inspection: Visual Inspection (VI), also called difficult in post-menopausal women. A condylomatous
down-staging or unaided visual inspection, consists of a lesion may noy stain or only partially stain with the
clinical examination of the cervix using only a speculum solution. Areas of leukoplakia (hyperkeratosis) and areas
and a light source. Visual inspection is subjective and partially denuded of squamous epithelium do not stain
therefore definition of test results should be standardized. with iodine and remain colorless (IARC, 2005). 
In fact, test positivity is defined by the presence or the
absence of specific characteristics, usually with low and Colposcopy: Colposcopy is a procedure that allows
high thresholds for positivity. Results are available illuminated stereoscopic and magnified (× 6-40) viewing of
without delay. the cervix and vagina. The women is placed in the
Over the last 10 years, the use of dilute (3-5%) acetic lithotomy position, with the cervix exposed with a bivalve
acid applied to the cervix before inspection, so known as speculum  in  place and various solutions-normal saline,
Visual Inspection with Acetic acid (VIA) has been 3-5% dilute acetic acid and Lugol’s iodine-are applied in
investigated. VIA involves naked eye inspection of the sequence. The aim is to examine the transformation zone.
cervix one minute after application of a 3-5% solution of The modern colposcope is a binocular microscope
acetic acid using a cotton swab or a spray. Test positivity with a variable-intensity light source, providing a
is based on the appearance of acetowhite areas in the stereoscopic view of the cervix with a field of view and
transformation zone, close to the squamocolumnar depth of focus that varies inversely with the magnification
junction or the os. The cervix is examinated using a bright selected. 
light source such as a torch or a halogen focus lamp. VIA Terminology  to  describe  the  morphological
is also known as Direct Visual Inspection (DVI), Acetic findings  in  a  standard  way  has  evolved  over  the
Acid Test (AAT) and cervicoscopy. years; many descriptions have been classified as to the
Cervigography can then be performed. Cervicograms degree of abnormality and have been combined into a
are replicate photographs of the cervix taken after scoring  system.  Biopsies are obtained under colposcopic
stains partially with Lugol’s iodine, making interpretation
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visualization from the locations with the most severe to follow-up women only with a negative test result for
changes, in order to histologically confirm the degree of human papillomavirus (Bhaumik et al., 2004). The addition
severity of the neoplastic process (IARC, 2005). of testing for human papillomavirus in women with low
HPV DNA testing the rate of repeat smears, but an increase in rates of
Overview: Research on the use of HPV DNA assays as a referral to colposcopy (Moss et al., 2006).
potential cervical cancer screening tool began in the late HPV DNA testing by home obtained samples is
1980s.  There  is  much  evidence that screening of women useful as  a screening tool for cervical cancer
with  both  cytology  and HPV DNA tests increases (Nobbenhuis et al., 2002). In fact, self-assessment for HPV
sensitivity for detection of Cervical Intraepithelial DNA is an easy, feasible and well-accepted method of
Neoplasia (CIN) 3 or cancer sufficiently to permit longer testing for HPV and for cervical cancer in tertiary referral
screening intervals than with cytology alone. This is one internal medicine outpatient clinics (Dannecker et al.,
of the facts that led the US FDA to approve the second- 2004). However, participation in the screening programme
generation hybrid capture assay (HC2) as an adjunct to remains the best option (Nobbenhuis et al., 2002). 
cytological testing for women aged 30 years and older
(IARC, 2005). Performance of HPV DNA detection Hybrid capture™ assay: Most clinical investigations of
methods as related to international standards will facilitate HPV testing have used first-or second-generation Hybrid
comparisons of data from multiple studies. Thus, the Capture™ (HC) systems, the only HPV test currently
availability of international HPV DNA standards will approved by the US FDA. The HC system is a nucleic
contribute to the field of HPV prevention, diagnosis and acid hybridization assay with signal amplification for the
treatment (Qiunt et al., 2006). qualitative detection of DNA of high-risk HPV types in
Techniques to detect the presence of HPV in cervical cervical specimens. It cannot however determine the
cell  specimens  have  evolved  considerable  in  the  last specific HPV type present, since detection is performed
25 years from: with a combined probe mix.
C Simple scoring of koilocytes in cervical smears to. detection system and probed for only nine of the high-risk
C Immunocytochemical staining to. HPV types. The second-generation HC system (HC2) has
C Nonamplified nucleic acid hybridization methods improved reagents and is based on a microplate assay lay-
such as dot blot, Southern blot and filter in-situ out that targets 13 high-risk HPV types. It uses long
hybridization and finally to. synthetic RNA probes that are complimentary to the DNA
C Signal-amplified, immunoassay-based nucleic acid sequence of 13 high-risk HPV types. The initial reaction
hybridization techniques such as the Hybrid step denatures the exfoliated cells in STM, thus releasing
Culture™ (HC) assay and a variety of Polymerase host and any existing HPV DNA molecules to the
Chain Reaction (PCR) techniques (IARC, 2005). solution. HPV DNA molecules then hybridize with the
The major obstacles to widespread acceptance of DNA-RNA hybrids reflecting the composition of HPV
HPV testing in cervical cancer are its high unit cost and types present in the mixture. This hybridization step
the fact that the technology is not in the public domain, as occurs inside the wells of a specially treated 96-well
it is for cervical cytology. Various studies have been plastic microtitration plate previously coated with
conducted as regards the cost-effectiveness of HPV DNA polyclonal IgG antibodies that are specific for RNA-DNA
testing. In a study carried out by Kim et al. (2005) it was hybrids, regardless of sequence homology. Any such
concluded that the use of HPV DNA testing, either for hybrids will then be captured by the solid-phase-bound
triage of women of any age with equivocal cytology antibodies. 
results, or for primary screening in conjunction with After washing steps to remove unbound molecules,
cytology in women >30 years of age, has the potential to a solution of a conjugate reagent consisting of the same
improve health benefits at a reasonable cost compared anti-RNA-DNA hybrid antibody covalently linked with
with current screening programs in the United Kingdom, the enzyme alkaline phosphatase is added to the wells.
The Netherlands, Italy and France (Kim et al., 2005). The Conjugate  antibody  molecules  will  then  bind  to  any
most likely strategy to be cost-effective uses human solid-phase-bound hybrids. After further washing to
papillomavirus testing to triage all women with an initial remove unbound molecules, a solution containing a
borderline and mild smear result and with a normal chemiluminescent dioxetane substrate is added to the
colposcopic finding (Legood et al., 2006), using cytology wells. Cleavage of the substrate by the alkaline
grade cytological abnormalities resulted in a reduction in
The first-generation assay (HC1) was a tube-based
respective  RNA  probe,  resulting in the formation of
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phosphatase  releases a luminescent reactiotion produced has improved by the implementation of techniques such
into the solution. The intensity of the light emitted is
proportional to the amount of HPV DNA originally
present in the specimen and is measured by a luminometer
provided  with  the  system.  The  reaction  signal  of each
specimen is expressed on a scale relative to the average
reactivity measured in triplicate wells with a positive
control containing 1.0 pg of HPV 16 DNA per mL.
Specimens yielding RLUs greater than or equal to 1.0 are
considered positive.
The polymerase chain reaction: The Polymerase Chain
Reaction (PCR) is based on the repetitive replication of a
target sequence of DNA flanked at each end by a pair of
specific oligonucleotide primers, which initiate the
polymerase-catalysed reaction. Because of the
exponential increase in the amount of target DNA
sequence after a few reaction cycles of denaturation,
annealing and extension, PCR has very high levels of
molecular sensitivity. PCR is based on target amplification
with type-specific or consensus or general primers. The
latter are able to amplify sequences from several different
HPV  types.  The amplified DNA products can be revealed
with ethidium bromide staining following agarose or
polyacrylamide gel electrophoresis (IARC, 2005). A PCR-
based genechip (Easychip HPV Blot) detects more
samples with HPV infection than HC2 in those patients
with normal and ASCUS cytology for a broader HPV type
range, but it is comparable to HC2 as regards the
identification of oncogenic HPV genotypes (Huang et al.,
2006). 
Recently, the commercially manufactured PCR-based
Roche AMPLICOR (AMP), which recognizes a group of
13 HR HPV types simultaneously (van Ham et al., 2005);
and LINEAR ARRAY (LA) HPV tests have become
available for HPV detection. Both are relatively easy to
use and provide a rapid and standardized method for
detecting and genotyping HPV, respectively. They exhibit
greater sensitivity and lower specificity than HC2 for
detecting high risk HPV. Hence, both the AMP and the
LA  tests  can  be  used  in  the  detection of high-risk
HPV and to predict treatment success or failure, re-
infection  and/or  new infections. They can also be used
as an epidemiological  tool  for  prevalence  studies
(Stevens  et al., 2007).
CONCLUSION
The incidence of cervical cancer has declined in the
past few years, largely due to the widespread execution of
screening  programs.  The   classical  Papanicolaou  smear
as liquid-based cytology, which give more precise results.
More recently has been the development of techniques to
detect the presence of HPV DNA in cervical samples. In
fact, the Food and Drug Administration (FDA) approved
the second-generation hybrid capture assay (HC2) as an
adjunct to cytological testing for women aged 30 years
and older. This age group was chosen because most HPV
infections in the younger population clear up on their
own, that is, a woman may be positive for HPV at a
younger age but after age thirty, she becomes HPV-
negative. 
The benefits of HPV DNA testing in an ASCUS
patient can be summarized as follows: Detecting the
presence of a high-risk virus means that there is a greater
chance of developing dysplasia and therefore colposcopy
might be recommended. If a high-risk virus is not
detected, it means that ASCUS was caused by infection
with  another  organism,  by  infection  with  a  low-risk
HPV virus of it might be simply a false-positive result. In
these cases, another Pap smear can be done to confirm
results. 
Yet, although screening for precancerous disease of
the cervix has significantly reduced the incidence of
cervical cancer, cervical cancer still causes of a certain
degree of morbidity and mortality in many countries. It is
important that all women undergo regular screening tests,
because, if not so, the incidence of cervical cancer in a
particular population will not decrease. Educational
initiatives targeted to the female population from a young
age about the benefits of screening tests will surely lead
to further decrease in cervical cancer incidence that has
been observed over the last years. 
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